Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: J Immunother. 2013 May;36(4):276–286. doi: 10.1097/CJI.0b013e31829419f3

FIGURE 3. Number of molecules of TRECs per million of PBMC detected in the blood of patients increase during the course of the intervention independently of Leuprolide treatment.

FIGURE 3

Molecules of TREC in patients from age 23 through 85 yr (median = 52; n = 50) were analyzed by QC-PCR. The number of molecules of TRECs detected per million of PBMC in the blood of patients at baseline decreases with age (A). Analysis of blood testosterone levels in men (B) and estradiol levels in women (C) after Leuprolide treatment. Most men had testosterone levels compatible with clinical castration (50 ng/dL), whereas almost all women had postmenopausal estradiol levels (24 pg/ml), after 2 doses of Leuprolide. At 24 weeks post-vaccine, most patients showed an increase in total TREC cells/million PBMC compared with pretreatment, independently of Leuprolide treatment (D). In 18 of 24 patients for the Leuprolide-treated, and 15 of 25 for the non-Leuprolide group, changes were deemed substantial (>25% increase).